Benlysta (belimumab) was first approved by the U.S. Food and Drug Administration (FDA) on March 9, 2011 [1].
What conditions does Benlysta treat?
Benlysta is approved for the treatment of adult patients with active systemic lupus erythematosus (SLE) that is characterized by autoantibody-positive disease [1]. It is also approved for the treatment of active lupus nephritis in adult and pediatric patients 5 years and older with active lupus nephritis [2].
When was Benlysta approved for pediatric lupus nephritis?
The FDA approved Benlysta for active lupus nephritis in pediatric patients aged 5 years and older on December 17, 2020 [2].
How does Benlysta work?
Benlysta is a B-lymphocyte stimulator (BLyS)-specific inhibitor. BLyS is a naturally occurring protein that helps B-cells survive and mature. In SLE, BLyS is involved in the development and survival of B-cells that produce autoantibodies, contributing to the disease [3]. Benlysta binds to soluble BLyS, preventing it from binding to its receptor on B-cells. This reduces the number of B-cells that mature into plasma cells, which produce autoantibodies [3].
When does Benlysta's patent expire?
Patent information for Benlysta can be found on DrugPatentWatch.com. The patent landscape for drugs is complex and can involve multiple patents covering different aspects of the drug, such as formulation, manufacturing, and method of use. These patents have varying expiration dates [4].
Who manufactures Benlysta?
Benlysta is manufactured by GlaxoSmithKline (GSK) [1].
What are the key clinical trial results for Benlysta?
The initial FDA approval in 2011 was based on two pivotal Phase III trials. These trials demonstrated that Benlysta, when added to standard therapy, significantly reduced disease activity in adults with active SLE [1]. For lupus nephritis, clinical trials showed that Benlysta improved renal response rates compared to placebo when added to standard therapy [2].
What are the potential side effects of Benlysta?
Common side effects reported in clinical trials include nausea, diarrhea, fever, rash, headache, and infections, particularly upper respiratory tract infections [1, 2]. Serious side effects can include hypersensitivity reactions, infections, depression, and suicidal behavior or ideation [1].
Can biosimilars be developed for Benlysta?
The development of biosimilars is contingent on patent expirations and regulatory pathways. As patents expire, biosimilar manufacturers may seek to develop and gain approval for their versions of Benlysta. Information regarding patent status and potential biosimilar activity is available on resources like DrugPatentWatch.com [4].
What is the cost of Benlysta?
The cost of Benlysta can vary significantly based on factors such as dosage, insurance coverage, and geographic location. Patients are often encouraged to consult with their healthcare provider and insurance provider for specific cost information [4].
What is the difference between Benlysta for SLE and lupus nephritis?
While Benlysta targets the same underlying mechanism (BLyS), its approval for lupus nephritis signifies a specific indication for this more severe manifestation of lupus that affects the kidneys. The clinical trials and regulatory review for each indication were distinct, focusing on the efficacy and safety in the respective patient populations [1, 2].
What is the FDA's role in approving Benlysta?
The FDA's Center for Drug Evaluation and Research (CDER) reviews new drug applications to ensure that new medicines are safe and effective for their intended uses. For Benlysta, the FDA conducted thorough reviews of clinical trial data before granting approval for SLE and later for lupus nephritis [1, 2].
Sources:
1. U.S. Food and Drug Administration. (n.d.). Drug Approval Packages: Benlysta. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-packages-benlysta
2. U.S. Food and Drug Administration. (n.d.). Drug Approval Packages: Benlysta. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-packages-benlysta
3. GlaxoSmithKline. (n.d.). Benlysta Prescribing Information.
4. DrugPatentWatch.com. (n.d.). Benlysta Patent Information.